Drug Trial Radar · NCT05039931
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Sep 15, 2021
Primary completion
Jun 2023
Study completion Jun 2023
Sponsor
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- SystImmune Inc.
- First posted
- Sep 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in participants with locally advanced or metastatic solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-035.
Conditions
- Breast Cancer
- Solid Tumor
Interventions
GNC-035Drug
Administration by intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: Up to 2 weeks
- MTD or MADTime frame: Up to 2 weeks
- TEAETime frame: Up to 2 years
- The recommended dose for future clinical studyTime frame: Up to 2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Sichuan, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.